MIT sheds light on how tumor cells formJune 22, 2006MIT cancer researchers have discovered a process that may explain how some tumor cells form, a discovery that could one day lead to new therapies that prevent defective cells from growing and spreading. The work was reported June 8 in the advance online issue of The EMBO Journal, a publication of the European Molecular Biology Organization (EMBO). Tumor cells that grow aggressively often have an irregular number of chromosomes, the structures in cells that carry genetic information. The normal number of chromosomes in a human cell is 46, or 23 pairs. Aggressive tumor cells often have fewer or more than 23 pairs of chromosomes, a condition called aneuploidy. To date it has not been clear how tumor cells become aneuploid. "Checkpoint proteins" within cells work to prevent cells from dividing with an abnormal number of chromosomes, but scientists have been puzzled by evidence that aneuploidy can result even when these proteins appear to be normal. What MIT researchers have discovered is a reason these checkpoint proteins may be unable to sense the defective cells, which tend to have very subtle errors in them. (These subtle errors are believed to be the cause of aneuploidy and the rapid growth of tumors.) Before cells divide, individual chromosomes in each pair of chromosomes must attach to a set of tiny structures called microtubules. If they attach correctly, the checkpoint proteins give them the go-ahead to divide. If they don't, the checkpoint proteins are supposed to stop them from dividing. "The checkpoint proteins are like referees in a tug-of-war contest," said Viji Draviam, a research scientist in MIT's Department of Biology and lead author of the paper. "They make sure that all chromosomes are lined up in the right places before the cell is allowed to divide." Scientists have known about the function of checkpoint proteins for at least 20 years, and they have suspected that mutations in checkpoint proteins cause the irregular number of chromosomes in the aneuploid cells. But they have been perplexed by the infrequent occurrence of mutations in aneuploid tumors. "It's puzzling that the suspected culprits — the aneuploidy-inducing checkpoint mutations — are rarely found at the scene of the crime, in the aneuploid tumors," Draviam said. That lingering question prompted Draviam and her colleagues to study how two other key molecules — a known tumor suppressor protein called APC and its partner protein EB1 — work together to assure that cells divide normally. They discovered that if they removed either protein from a cell or if they interrupted the way the proteins work together, the cell would become aneuploid. In other words, the checkpoint proteins need to sense that the APC and EB1 proteins both are present for normal cell division to take place. "This is important because it is the first demonstration that interrupting the normal function of these proteins will cause the cell to become aneuploid," Draviam said. "Our research sheds light on what could go wrong to cause an irregular number of chromosomes in cells even when the checkpoint proteins appear to be functioning properly." Draviam's co-authors are graduate students Irina Shapiro and Bree Aldridge and MIT Professor of Biology and Biological Engineering Peter Sorger. The research was funded by the National Institutes of Health. Massachusetts Institute of Technology |
|||||||||||||||||||||
| Related Tumor Cells Current Events and Tumor Cells News Articles New cancer target for non-Hodgkin's lymphoma Physician-scientists from Weill Cornell Medical College have discovered a molecular mechanism that may prove to be a powerful target for the treatment of non-Hodgkin's lymphoma, a type of cancer that affects lymphocytes, or white blood cells. Cancers' Sweet Tooth May Be Weakness The pedal-to-the-metal signals driving the growth of several types of cancer cells lead to a common switch governing the use of glucose, researchers at Winship Cancer Institute of Emory University have discovered. UCLA researchers create 'fly paper' to capture circulating cancer cells Just as fly paper captures insects, an innovative new device with nano-sized features developed by researchers at UCLA is able to grab cancer cells in the blood that have broken off from a tumor. 'Cross-talk' mechanism contributes to colorectal cancer Researchers at the University of Wisconsin-Madison School of Medicine and Public Health have identified a molecular mechanism that allows two powerful signaling pathways to interact and begin a process leading to colorectal tumors. CSHL study shows that some malignant tumors can be shut down after all Oncologists have had their hands tied because more than half of all human cancers have mutations that disable a protein called p53. 1930s drug slows tumor growth Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease. New Notre Dame study provides insights into the molecular basis of tumor cell behavior A new study by a team of researchers led by Crislyn D'Souza-Schorey, associate professor of biological sciences at the University of Notre Dame, sheds light on the molecular basis by which tumor cells modulate their surroundings to favor cancer progression. Immune therapy can protect against or treat later lymphoma Specially developed immune system cells that target the common Epstein-Barr virus can protect immune-suppressed bone marrow transplant recipients against lymph system disease and cancers that arise from the viral infection. Study reveals a 'missing link' in immune response to disease The immune system's T cells have the unique responsibilities of being both jury and executioner. They examine other cells for signs of disease, including cancers or infections, and, if such evidence is found, rid them from the body. Precisely how T cells shift so swiftly from one role to another, however, has been a mystery. Discovery offers potential new pancreatic cancer treatment Tiny particles that can carry drugs and target cancer cells may offer treatment hope for those suffering with pancreatic cancer. New research to be presented in November at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting in Los Angeles reveals that tumor-penetrating microparticles (TPM) have been specifically designed to break through hard-to-infiltrate barriers and deliver drugs more effectively and efficiently than the standard form of chemotherapy such as those injected through a vein. More Tumor Cells Current Events and Tumor Cells News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||